drugset / Trial / NCT03901352
Study of Mirogabalin for Central Neuropathic Pain
RandomizedParallel-groupTriple-blindTreatment
Summary
Investigate the efficacy and safety of mirogabalin in participants with central neuropathic pain in comparison to placebo
Timeline
- Start
- 2019-03-12
- Primary completion
- 2020-12-28
- Completion
- 2020-12-28
Publications
- Hosomi K, Katayama Y, Sakoda H, Kikumori K, Kuroha M, Ushida T. Usefulness of Mirogabalin in Central Neuropathic Pain After Stroke: Post Hoc Analysis of a Phase 3 Study by Stroke Type and Location. Pain Ther. 2024 Oct;13(5):1151-1171. doi: 10.1007/s40122-024-00616-3. Epub 2024 Jul 4.
- Ushida T, Katayama Y, Hiasa Y, Nishihara M, Tajima F, Katoh S, Tanaka H, Maeda T, Furusawa K, Kakehi Y, Kikumori K, Kuroha M. Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia. Pain Ther. 2023 Aug;12(4):963-978. doi: 10.1007/s40122-023-00513-1. Epub 2023 Apr 28.
- Ushida T, Katayama Y, Hiasa Y, Nishihara M, Tajima F, Katoh S, Tanaka H, Maeda T, Furusawa K, Richardson M, Kakehi Y, Kikumori K, Kuroha M. Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia. Neurology. 2023 Mar 14;100(11):e1193-e1206. doi: 10.1212/WNL.0000000000201709. Epub 2022 Dec 14.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirogabalin | Small molecule | 10 mg | Oral |
| Subject | Mirogabalin | Small molecule | 15 mg | Oral |
| Subject | Mirogabalin | Small molecule | 20 mg | Oral |
| Subject | Mirogabalin | Small molecule | 30 mg | Oral |